119 results on '"Janssen, Jeroen J. W. M."'
Search Results
2. Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia
3. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial
4. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes.
5. S155: PROGNOSTIC FACTORS FOR 3-YEAR MAJOR MOLECULAR RESPONSE MAINTENANCE IN CHRONIC MYELOID LEUKAEMIA PATIENTS IN THE EUROPEAN STOP KINASE INHIBITORS (EURO-SKI) TRIAL
6. S159: HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY
7. Validation of the EUTOS long-term survival score in a recent independent cohort of “real world” CML patients
8. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
9. Clinical impact of PCR-based Aspergillus and azole resistance detection in invasive aspergillosis. A prospective multicenter study
10. A Systematic Review of the Evidence of Hematopoietic Stem Cell Differentiation to Fibroblasts
11. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis
12. Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
13. DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia
14. Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification
15. Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML
16. Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors
17. Correction:Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989–2017 (Leukemia, (2020), 34, 12, (3408-3412), 10.1038/s41375-020-0902-1)
18. Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells
19. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
20. MRD Tailored Therapy in AML: What We Have Learned So Far
21. IGFBP7 activates retinoid acid–induced responses in acute myeloid leukemia stem and progenitor cells
22. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy
23. Collaboration Around Rare Bone Diseases Leads to the Unique Organizational Incentive of the Amsterdam Bone Center
24. Insulin-like Growth Factor Binding Protein 7 Activates the Retinoid Acid Differentiation Pathway in Acute Myeloid Leukemia Cells
25. Targeting miRNA-551b, a "Stemness"-like microRNA, to Eradicate AML (Stem) Cells
26. RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML
27. Patient satisfaction with information on oral anticancer agent use
28. Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation
29. No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial
30. Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial
31. Phosphoproteomics of a panel of AML cell lines reveals oncogenic signaling and candidate drivers
32. Patient satisfaction with information on oral anticancer agent use.
33. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy
34. Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib
35. Restoration of the human stem cell niche after stem cell transplantation
36. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia
37. Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia.
38. Autologous Stem Cell Transplantation in elderly Acute Myeloid Leukemia.
39. RNA-based FLT3-YTD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML.
40. Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase:ENEST1st sub-analysis
41. High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population.
42. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.
43. Reply to the Comment on Association of FLT3 -internal tandem duplication length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis
44. Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population.
45. Association of FLT3-internal tandem duplication length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis.
46. Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters.
47. The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era.
48. Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity.
49. Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines.
50. IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.